2026 Sensory neuronopathy indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Paraneoplastic cerebellar degeneration indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and…

2026 Progressive encephalomyelitis with rigidity and myoclonus indication strategy covering epidemiology, GLRA1 biology, active trials, transactions, unmet need,…

2026 Opsoclonus-myoclonus syndrome indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…

2026 LGI1 antibody encephalitis indication strategy covering epidemiology, LGI1 biology, active trials, transactions, unmet need, competition and market…

2026 Limbic encephalitis indication strategy covering epidemiology, NMDA receptor biology, active trials, transactions, unmet need, competition and market…

2026 Bickerstaff brainstem encephalitis indication strategy covering epidemiology, C5 biology, active trials, transactions, unmet need, competition and market…

2026 Hashimoto encephalopathy indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…

2026 IgG4-related aortitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Acute hemorrhagic leukoencephalitis indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…

2026 Amyloid beta-related angiitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…

2026 Cerebral amyloid angiopathy-related inflammation indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need,…